Clinical trials: Progressive Gliosarcoma
Brain and Central Nervous System Tumors
Gimatecan in Treating Patients With Recurrent or Progressive Primary Malignant Glioma
RATIONALE: Drugs used in chemotherapy, such as gimatecan, work in different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00087061
- Testing
- gimatecan
- Where
- United States
- Sponsor
- Jonsson Comprehensive Cancer Center
Brain and Central Nervous System Tumors
Alanosine in Treating Patients With Progressive or Recurrent Malignant Gliomas
RATIONALE: Drugs used in chemotherapy, such as alanosine, use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00075894
- Testing
- L-alanosine
- Where
- 5 sites in United States
- Volunteers
- 18 people
- Sponsor
- National Cancer Institute (NCI)
Glioblastoma, Gliosarcoma
Ph. I Temozolomide + O6-BG + Irinotecan in Treatment of Pts w Recurrent / Progressive Cerebral Anaplastic Gliomas
Objectives: To determine maximum tolerated dose of CPT-11 when administered following Temodar plus O6-benzylguanine To characterize any toxicity associated w combo of CPT-11 + Temodar plus O6-BG To observe pts for clinical…
- Trial name
- NCT00612638
- Testing
- Temodar, O6-BG, and Irinotecan
- Where
- United States
- Volunteers
- 96 people
- Sponsor
- Duke University
Brain and Central Nervous System Tumors
Bevacizumab in Treating Patients With Recurrent or Progressive Glioma
RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00337207
- Testing
- bevacizumab
- Where
- 2 sites in United States
- Volunteers
- 55 people
- Sponsor
- Northwestern University
Glioblastoma, Gliosarcoma
Phase II Imatinib + Hydroxyurea in Treatment of Patients With Recurrent/Progressive Grade II Low-Grade Glioma (LGG)
Primary objective: To evaluate activity of imatinib mesylate and hydroxyurea among patients with progressive/recurrent grade II low-grade glioma (LGG) as measured by 12-month progression free survival Secondary objectives: To…
- Trial name
- NCT00615927
- Testing
- Imatinib Mesylate & Hydroxyurea
- Where
- United States
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Duke University
Brain Tumor, Anaplastic Astrocytoma
Ritonavir and Lopinavir in Treating Patients With Progressive or Recurrent High-Grade Glioma
RATIONALE: Ritonavir and lopinavir may stop the growth of gliomas by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Conditions
- Brain Tumor, Anaplastic Astrocytoma, Anaplastic Ependymoma, Anaplastic Oligodendroglioma
- Trial name
- NCT01095094
- Testing
- ritonavir, lopinavir
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Case Comprehensive Cancer Center
Cancer
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
This is a phase III, randomized, double-blind, placebo-controlled, multicenter study of the clinical response to fentanyl sublingual spray as a treatment for breakthrough cancer pain.
- Trial name
- NCT00538850
- Testing
- Fentanyl sublingual spray
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- INSYS Therapeutics Inc
Brain and Central Nervous System Tumors
Tipifarnib in Treating Patients With Recurrent or Progressive Malignant Glioma
RATIONALE: Tipifarnib may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth. PURPOSE: Phase II trial to study the effectiveness of tipifarnib in treating patients who have recurrent or…
- Trial name
- NCT00005859
- Testing
- tipifarnib
- Where
- 11 sites in United States
- Volunteers
- 136 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Brain and Central Nervous System Tumors
Chemotherapy in Treating Patients With Progressive or Recurrent Brain Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I/II trial to study the effectiveness of irofulven in treating patients who have progressive…
- Trial name
- NCT00012038
- Testing
- irofulven
- Where
- 10 sites in United States
- Sponsor
- New Approaches to Brain Tumor Therapy Consortium